Toronto-based psychedelic pharmaceutical company founded in 2018, focused on sub-perceptual, non-hallucinogenic low-dose treatments for neuropsychiatric conditions. Its lead program is a Phase 2 trial of repeated low-dose psilocybin for generalized anxiety disorder, alongside a pipeline of tryptamine analogs and serotonin/neurotrophic receptor modulators.
Diamond Therapeutics News 7 articles
- Diamond Therapeutics Announces First Patient Enrolled in FDA-authorized Study Evaluating Low-Dose Psilocybin in Human Subjects with Demoralization
- Diamond Equity Research Initiates Coverage on Enveric Biosciences Inc. (NASDAQ: ENVB)
- First Avenue Ventures Life Science Fund I Invests in Diamond Therapeutics to Accelerate Innovation in Mental Health
- Diamond Therapeutics Announces FDA-authorized Clinical Trial of Low-Dose Psilocybin in Collaboration with University of Alabama at Birmingham
- Diamond Therapeutics Announces FDA-authorized Clinical Trial of Low-Dose Psilocybin in Collaboration with University of Alabama at Birmingham
- Diamond Therapeutics Announces Health Canada Approval of Phase 2 Clinical Trial with Low-Dose Psilocybin
- Diamond Therapeutics completes Phase I clinical study of low-dose psilocybin in healthy human subjects